-- カナダ統計局は月曜日、2月に発行された建築許可の総額が前月比11億ドル(8.4%)減の121億ドルになったと発表した。 カナダ統計局の声明によると、建設意向の減少は非住宅部門の13億ドル減が主因で、住宅部門の1億3560万ドル増が減少幅を相殺した。 また、カナダ統計局は、2月の建築許可総額は、実質ベース(2023年=100)では前月比8.6%減、前年同月比11.5%減となったと付け加えた。 2月の非居住用建築許可額は前月比24.0%減となり、2023年4月以来最大の減少幅を記録しました。減少の大部分は公共施設(9億8,720万ドル減)によるもので、商業施設(1億6,000万ドル減)と工業施設(1億470万ドル減)の減少幅は比較的小さくなっています。 居住用部門では、集合住宅(1億8,030万ドル増)の増加が見られましたが、一戸建て住宅(4,470万ドル減)の減少によって一部相殺されました。 このデータは、居住用(一戸建て住宅および集合住宅)と非居住用(工業施設、商業施設、公共施設)の建築許可額を示しています。許可を発行する自治体への調査に基づいて算出され、建設業界は季節変動の影響を受けやすいため、季節調整が行われています。これはカナダの建設業界の先行指標です。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.